Article contentThis press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “exp ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric†or the "Company†), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of U.S. Patent No. 12,492,179 entitled, "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives†(the "'179 patent†), with claims to compositions and methods of treatment for novel molecules with the potential to be developed. ...

or the "Company†), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98 per share, res. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric†...

or the "Company†), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric†...

Core Insights - The stock market has experienced significant movements among top gainers, with notable price changes and trading volumes in various sectors [1] Company Summaries - Beasley Broadcast Group, Inc. (BBGI) saw its stock price surge to $17.74, a 338.27% increase, with a trading volume exceeding 35 million shares, following a third-quarter revenue report of $51 million [2][7] - ASPAC III Acquisition Corp. (ASPC) experienced a stock price increase to $24.3, up by 131.87%, on a volume of approximately 2.87 million shares, driven by investor interest in potential mergers or acquisitions [3][7] - ASPAC's unit, ASPCU, also saw its stock rise to $24.11, a 129.40% increase, with a trading volume of around 51,758 shares, reflecting similar investor sentiment [3][7] - Enveric Biosciences, Inc. (ENVB) had its stock price increase to $10.15, up by 71.61%, with trading volume over 32 million shares, following a significant patent allowance for its EVM301 Series molecules [4][7] - Creative Global Technology Holdings Limited (CGTL) reported a stock price climb to $1.09, a 65.18% increase, with over 21 million shares traded, highlighting investor interest in its recycled consumer electronics business model [5][7] Market Dynamics - The movements in stock prices underscore the dynamic nature of the market, with companies across various sectors experiencing significant volatility, attracting investor attention for future developments [6]

Market Overview - U.S. stocks showed mixed performance with the Dow Jones index gaining over 200 points, up 0.50% to 47,799.21, while NASDAQ fell 0.18% to 23,533.49 and S&P 500 rose 0.11% to 6,849.05 [1] - Industrial shares increased by 0.8%, while information technology stocks decreased by 0.6% [1] Commodity Market - U.S. crude oil inventories decreased by 1.812 million barrels, contrasting with a gain of 0.574 million barrels in the previous week and against market expectations of a 2.3 million barrel decline [2][9] - Oil prices fell by 0.8% to $57.78, while gold decreased by 0.3% to $4,225.70; silver rose by 0.5% to $61.150, and copper increased by 0.7% to $5.3550 [4] European Market - European shares were mixed, with the eurozone's STOXX 600 rising 0.05%, Spain's IBEX 35 Index up 0.12%, and London's FTSE 100 up 0.23%. In contrast, Germany's DAX 40 fell 0.17% and France's CAC 40 decreased by 0.45% [5] Asian Market - Asian markets closed mostly lower, with Japan's Nikkei down 0.10%, Hong Kong's Hang Seng up 0.42%, China's Shanghai Composite down 0.23%, and India's BSE Sensex down 0.32% [6] Company Performance - Photronics Inc (NASDAQ:PLAB) shares surged 35% to $34.66 after reporting better-than-expected fourth-quarter results and issuing first-quarter guidance above analyst estimates [8] - Braze Inc (NASDAQ:BRZE) shares increased by 16% to $35.42 following an upward revision of FY2026 adjusted EPS and sales guidance after strong third-quarter revenue [8] - Enveric Biosciences, Inc. (NASDAQ:ENVB) shares rose 78% to $10.56 after receiving a Notice of Allowance for a patent application related to its EVM301 Series molecules [8] - AeroVironment, Inc. (NASDAQ:AVAV) shares fell 10% to $252.56 after reporting mixed earnings and guidance [8] - Mama's Creations Inc (NASDAQ:MAMA) shares dropped 9% to $13.03 despite reporting positive third-quarter financial results [8] - Pomdoctor Limited (NASDAQ:POM) shares plummeted 73% to $1.4799 [8] Economic Indicators - U.S. compensation costs for civilian workers rose by 0.8% in the third quarter, compared to a 0.9% gain in the previous period [7]

Market Overview - US stock futures showed slight gains ahead of the Federal Reserve's policy decision, with Dow futures hovering around 47,635, S&P 500 futures at 6,856, and Nasdaq 100 futures at 25,724.25 [1][2] - The market is pricing in a 90% probability of a quarter-point rate cut by the Fed, indicating strong expectations for monetary easing [1][2] Federal Reserve Insights - The Federal Open Market Committee (FOMC) is experiencing internal divisions, with some officials advocating for easier policy to support a cooling labor market, while others caution that further cuts could risk inflation as price pressures stabilize [2][5] - The cautious tone in equities reflects traders' reluctance to take large positions until the Fed provides clarity on its 2026 policy path [5][6] Stock Market Movements - Tuesday's trading session lacked clear direction, with the Dow Jones Industrial Average declining due to weakness in JPMorgan, while the Nasdaq Composite saw slight gains driven by Tesla and Alphabet [6] - Upcoming earnings reports from Oracle, Broadcom, Costco, and Lululemon are anticipated as key indicators for market performance, particularly in AI-driven cloud spending [6] Silver Market Dynamics - Silver prices reached a historic high of $61.47 per ounce, reflecting a significant rally driven by severe supply tightness, elevated borrowing rates, and speculative bets on a Fed rate cut [10][11] - Silver has more than doubled in 2025, outperforming gold's 60% increase, with a major supply crunch in October contributing to the price surge [12] - Despite some inventory returning to London vaults, high borrowing costs indicate ongoing supply tightness, compounded by decade-low Chinese inventories affecting global supply chains [12]

Core Insights - Enveric Biosciences Inc. (NASDAQ:ENVB) shares experienced a significant increase of 73.82% in after-hours trading, reaching a price of $10.29, following a closing price of $5.92, which was down 2.47% on the same day [1]. Patent Announcement - The company received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application related to its EVM301 Series molecules, aimed at potential treatments for mental health disorders [2]. - The patent titled "N-heterocycle substituted tryptamine derivatives and methods of using" includes claims that could broaden Enveric's pipeline by covering additional neuroplastogenic, non-hallucinogenic molecules for treating neuropsychiatric and addiction disorders [3]. Product Development - The patent is expected to strengthen Enveric's EVM301 Series portfolio, which features its lead asset, EB-003, a non-hallucinogenic serotonin receptor agonist under development for depressive and anxiety disorders [4]. Company Strategy - Joseph Tucker, Director and CEO of Enveric, emphasized the importance of reinforcing the patent estate around EB-003 and the EVM301 Series of compounds to generate value for shareholders [5]. Stock Performance - Despite the recent surge, ENVB stock has seen a substantial decline of 91.57% year-to-date, with a market capitalization of $3.45 million and an annual trading range between $4.88 and $96.30 [5]. - Benzinga Edge Stock Rankings indicate a negative price trend for ENVB across all time frames [6].

Financial Performance - For the three months ended September 30, 2025, total operating expenses were $1,873,943, a decrease of approximately 10% from $2,083,192 in the same period of 2024[97]. - The net loss for the three months ended September 30, 2025, was $1,873,669, compared to a net loss of $2,084,032 for the same period in 2024, reflecting an improvement of approximately 10%[97]. - The company incurred a loss from operations of $6,580,525 for the nine months ended September 30, 2025, contributing to an accumulated deficit of $112,652,321[104]. - Net cash used in operating activities was $6,356,680 for the nine months ended September 30, 2025, compared to $6,414,590 in 2024[108]. - Cash on hand as of September 30, 2025, was $3,757,594, which is insufficient to meet operating cash needs for the next 12 months[105]. - Management has substantial doubt about the company's ability to continue as a going concern for a period of one year from the issuance of the financial statements[106]. Expenses - General and administrative expenses increased by $235,496, or 20%, to $1,431,157 for the three months ended September 30, 2025, primarily due to higher marketing and legal expenses[98]. - General and administrative expenses decreased to $4,010,313 for the nine months ended September 30, 2025, from $4,329,565 for the same period in 2024, a decrease of 7%[101]. - Research and development expenses decreased by $400,300, or approximately 50%, to $402,417 for the three months ended September 30, 2025, driven by reduced costs in various areas[99]. - Research and development expenses increased to $2,408,839 for the nine months ended September 30, 2025, from $1,873,873 in 2024, an increase of approximately 29%[102]. - The Company experienced a significant decrease in depreciation and amortization expense, which fell by approximately 52% to $40,369 for the three months ended September 30, 2025, due to full amortization of intangible assets[100]. - Depreciation and amortization expense decreased to $161,373 for the nine months ended September 30, 2025, from $255,002 in 2024, a decrease of approximately 37%[103]. Equity and Financing - The Company reported stockholders' equity of $3,456,176 as of September 30, 2025, regaining compliance with Nasdaq Listing Rule 5550(b)(1)[95]. - The Company entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell shares of Common Stock with an aggregate offering price of up to $1,854,151, raising net cash proceeds of $1,636,799 as of September 30, 2025[91]. - Net cash provided by financing activities was $7,890,361 for the nine months ended September 30, 2025, compared to $7,210,386 in 2024[111]. - The company has not generated revenue since inception and has relied on debt and equity financing to fund operations[104]. Compliance and Risks - The Company received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to a stock price below $1.00 but subsequently regained compliance following a 1-for-12 reverse stock split[96]. - The company is subject to foreign currency exchange rate risk due to transactions in Canadian and Australian dollars[116]. Product Development - The Company plans to advance its lead drug candidate EB-003 through preclinical studies and aims to initiate first-in-human studies to assess safety and tolerability[88]. - The EVM401 Series was unveiled on February 25, 2025, to broaden the pipeline with additional non-hallucinogenic molecules targeting addiction and neuropsychiatric disorders[90].

Financial Results - Enveric Biosciences, Inc. reported its financial results for Q3 2025, ending September 30, 2025[4] - Specific financial metrics and performance data were included in the press release, which is referenced as Exhibit 99.1[4] Corporate Update - The company issued a corporate update alongside the financial results on November 14, 2025[4]